EGFR and lung adenocarcinoma: The EGFR L833V mutation was mostly reported to be accompanied with H835L with or without other mutations in only 11 NSCLC patients reported by now.[8,9] Here, we report a patient with stage III lung adenocarcinoma harboring rare EGFR G719A/L833V mutations, and a beneficial clinical effect was observed after icotinib treatment.